TY - JOUR
T1 - Indications for and use of long-acting injectable antipsychotics
T2 - Consideration from an inpatient setting
AU - Kishimoto, Taishiro
AU - Sanghani, Sohag
AU - Russ, Mark J.
AU - Marsh, Akeem N.
AU - Morris, Joshua
AU - Basu, Suparna
AU - John, Majnu
AU - Kane, John M.
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed. Of 305 charts reviewed, consisting of 279 unique patients, 27.2% were judged to have an indication for an LAI (n=76), but only 32.9% of these (n=25) were discharged on an LAI. In the multiregression model, being African American, residing in a psychiatric residence, having a previous history of an LAI trial, and being treated with a higher antipsychotic dose were predictive of LAI prescription. It is important to focus on the population who are not likely to receive an LAI, but who have such indications for treatment.
AB - Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed. Of 305 charts reviewed, consisting of 279 unique patients, 27.2% were judged to have an indication for an LAI (n=76), but only 32.9% of these (n=25) were discharged on an LAI. In the multiregression model, being African American, residing in a psychiatric residence, having a previous history of an LAI trial, and being treated with a higher antipsychotic dose were predictive of LAI prescription. It is important to focus on the population who are not likely to receive an LAI, but who have such indications for treatment.
KW - antipsychotics
KW - chart review
KW - long-acting injectable
KW - prescription
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85011931090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011931090&partnerID=8YFLogxK
U2 - 10.1097/YIC.0000000000000165
DO - 10.1097/YIC.0000000000000165
M3 - Article
C2 - 28181959
AN - SCOPUS:85011931090
SN - 0268-1315
VL - 32
SP - 161
EP - 168
JO - International Clinical Psychopharmacology
JF - International Clinical Psychopharmacology
IS - 3
ER -